Last reviewed · How we verify

NCT02989870

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Withdrawn Phase 1 Last updated 5 June 2020
What this trial tests

Phase 1 trial testing Stereotactic Body Radiation Therapy (SBRT) in HepatoCellular Carcinoma. Withdrawn.

Timeline
27 March 2017
Primary endpoint
15 October 2018
15 October 2018

Quick facts

Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date27 March 2017
Primary completion15 October 2018
Estimated completion15 October 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with HepatoCellular Carcinoma or Unresectable HepatoCellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy. (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.) The type of radiation is called stereotactic body radiation therapy (SBRT). The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given along with the systemic therapies, sorafenib and bavituximab. The researchers want to see which dose of radiation will work best in stimulating the immune response and provide local control to the participant's liver. The usual treatment for hepatocellular carcinoma that is unresectable can be transarterial therapy, sorafenib alone and/or clinical trial.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma.
    Jiang J, Diaz DA, Nuguru SP, Mittra A, et al · · 2022 · cited 15× · PMID 36612046 · DOI 10.3390/cancers15010050
  2. Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.
    Sun X, Deng L, Lu Y. · · 2018 · cited 13× · PMID 29545728 · DOI 10.21147/j.issn.1000-9604.2018.01.15
  3. Efferocytosis: The Janus-Faced Gatekeeper of Aging and Tumor Fate.
    Liu Z, Li Y, Ren Y, Chen J, et al · · 2025 · cited 11× · PMID 39748782 · DOI 10.1111/acel.14467
  4. Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions.
    Zhang Y, Gu Y, Zhan M, Yang L, et al · · 2025 · cited 3× · PMID 41201667 · DOI 10.1186/s43556-025-00347-7
  5. Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic-cell clearance to therapeutic targeting.
    Yang Q, Yan J, Yang Q. · · 2026 · cited 1× · PMID 41601343 · DOI 10.1002/ctm2.70601

Verify or expand the search:

Other trials of Stereotactic Body Radiation Therapy (SBRT)

Trials testing the same drug.

Other recruiting trials for HepatoCellular Carcinoma

Currently open trials in the same condition.

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02989870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing